Deeply embattled over the trailing year and then some, biotechnology firm Novavax (NVAX) finally offered a bit of bright news. Earlier on Monday, the company announced a change of leadership, with current President and CEO Stanley C. Erck set to retire. Taking his place will be industry veteran John C. Jacobs, who will leave the helm at Harmony Biosciences (HRMY).

Per the accompanying press release, the executive shift will officially commence on Jan. 23, 2023. Erck will serve as an advisor to Novavax for the next 15 months to facilitate a smooth transition, per the statement. Conspicuously, NVAX stock gained 11.25% to close out the Monday session while HRMY dropped a bit over 16%, reflecting the respect Jacobs carries within the broader healthcare sector.

“As we prepare for Stan's retirement, the Board reflects on the incredible legacy he leaves behind,” said James F. Young, PhD, Chairman of the Board of Directors. “Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic.”

Further, Young added, “[t]his foundation puts Novavax in a strong position to execute on its long-term strategy, and we look forward to supporting Stan and John through the transition. John is a seasoned industry leader who will bring a fresh perspective and deep industry expertise to Novavax.”

On paper, Novavax securing Jacobs’ services should bolster NVAX stock. Per the announcement, Jacobs “brings more than 25 years of commercial, operations, business and leadership experience across multiple therapeutic areas.” Prior to his time at Harmony, he held leadership roles at Teva Pharmaceuticals (TEVA) beginning in 2014. Also, Jacobs worked in several other healthcare enterprises, including pharmaceutical giant Pfizer (PFE).

Although major challenges await NVAX stock – particularly its trailing-year loss of nearly 91% – options traders appear enthused, with Novavax derivative contracts garnering greater-than-normal interest.

NVAX Stock Lights Up the Screener for Unusual Options Activity

Following the close of the Jan. 9 session, NVAX stock represented one of the top 100 entries for unusual options activity. Specifically, traders moved in on the $14.50 calls with an expiration date of Jan. 20 – 11 days from the time the order was placed.

Volume reached 2,303 contracts against an open interest reading of 151. Further, the bid-ask spread as represented by the midpoint price (35 cents) came out to 22.86%, a steep figure. Ordinarily, a wide spread translates to an underlying option being less liquid due to fewer buyers and sellers for said contract.

Interestingly, the put-call open interest ratio for NVAX stock sits at 0.66. Typically, the delineation between bullish and bearish sentiment stands at around 0.70 (mathematically, it would be 1:1 but the market has an upward bias). Ratios below 0.70 indicate generally bullish sentiment as more traders are buying call than puts.

Adding to the optimism for NVAX stock is sentiment among analysts. Three months ago, Wall Street experts pegged Novavax as a consensus “moderate buy,” breaking down as four strong buys, one hold, one moderate sell and one strong sell. In the current month, the consensus view remains the same. However, one analyst gave up a strong buy view, downgrading it to hold.

Nevertheless, caution remains key for NVAX stock. According to Barchart’s technical analysis indicator, shares rate as an average 88% sell. In addition, the 60-month beta for NVAX pings at 1.89, which is significantly more volatile than the benchmark equities index.

Huge Challenges Ahead for Novavax

While a change at the top could help reinvigorate NVAX stock, the underlying enterprise still has a mountain of obstacles to climb. Therefore, investors need to exercise skepticism – it’s better to let Novavax prove to you that it’s worthy of your hard-earned money before placing large long-side wagers.

As mentioned earlier, NVAX stock collapsed to the tune of nearly 91% in the trailing year. In terms of the life of NVAX, stakeholders suffered more than an 85% loss of equity value. Whatever tricks the new CEO has up his sleeve, he must deploy them quickly and effectively.

Scientifically as well, Novavax presents major risks. Unlike other COVID-19 vaccine developers, Novavax went with the more traditional subunit (protein-based) approach. In contrast, its rivals went with the innovative messenger-RNA technology. So far, mRNA-based solutions have dominated the discourse.

What’s more, biotech firms like CureVac (CVAC) are busy leveraging the mRNA approach to develop vaccines for new indications, such as new COVID strains or the seasonal flu. Presumably, mRNA will be used to undergird a wide range of therapeutic solutions. Thus, Novavax’s insistence on staying the course with the subunit approach may be disadvantageous in terms of time and money.

Of course, with COVID-19 likely to become endemic, Novavax still enjoys a relevant fundamental backdrop. But aside from Monday’s big pop, it’s not the best way to play this pandemic. Therefore, only speculators should apply here.

• Stock Rally Fizzles on Hawkish Fed Comments
• Bullish Investors in Devon Energy Are Shorting Put Options Ahead of Earnings
• Unusual Options Activity Confirms Optimism for CureVac (CVAC) Amid ‘Tripledemic’
• Earnings Continue to be a Risk for Technology Stocks